Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

Figure 3

Kaplan–Meier curves of progression-free survival (PFS) from the discontinuation for other reasons than PD (n = 65) and according to the confirmed response during treatment, University Hospital of Bordeaux, 2019. The overall subgroup represents all the patients included in the cohort (n = 65). The subgroup CR represents the 25 patients who discontinued for CR, while 12 patients were in the PR/SD subgroup and 28 were in the toxicity subgroup. The hash marks designate patients who were censored at that time point. There was no statistically significant association between the cause of treatment discontinuation and PFS ().